|
US4419446A
(en)
|
1980-12-31 |
1983-12-06 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant DNA process utilizing a papilloma virus DNA as a vector
|
|
NZ201705A
(en)
|
1981-08-31 |
1986-03-14 |
Genentech Inc |
Recombinant dna method for production of hepatitis b surface antigen in yeast
|
|
US4601978A
(en)
|
1982-11-24 |
1986-07-22 |
The Regents Of The University Of California |
Mammalian metallothionein promoter system
|
|
US4560655A
(en)
|
1982-12-16 |
1985-12-24 |
Immunex Corporation |
Serum-free cell culture medium and process for making same
|
|
US4657866A
(en)
|
1982-12-21 |
1987-04-14 |
Sudhir Kumar |
Serum-free, synthetic, completely chemically defined tissue culture media
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
DD266710A3
(de)
|
1983-06-06 |
1989-04-12 |
Ve Forschungszentrum Biotechnologie |
Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
|
|
US4767704A
(en)
|
1983-10-07 |
1988-08-30 |
Columbia University In The City Of New York |
Protein-free culture medium
|
|
US4965199A
(en)
|
1984-04-20 |
1990-10-23 |
Genentech, Inc. |
Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
|
|
US4879231A
(en)
|
1984-10-30 |
1989-11-07 |
Phillips Petroleum Company |
Transformation of yeasts of the genus pichia
|
|
GB8516415D0
(en)
|
1985-06-28 |
1985-07-31 |
Celltech Ltd |
Culture of animal cells
|
|
US4927762A
(en)
|
1986-04-01 |
1990-05-22 |
Cell Enterprises, Inc. |
Cell culture medium with antioxidant
|
|
GB8610600D0
(en)
|
1986-04-30 |
1986-06-04 |
Novo Industri As |
Transformation of trichoderma
|
|
ATE135397T1
(de)
|
1988-09-23 |
1996-03-15 |
Cetus Oncology Corp |
Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
|
|
FR2646437B1
(fr)
|
1989-04-28 |
1991-08-30 |
Transgene Sa |
Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
|
|
EP0402226A1
(en)
|
1989-06-06 |
1990-12-12 |
Institut National De La Recherche Agronomique |
Transformation vectors for yeast yarrowia
|
|
US5122469A
(en)
|
1990-10-03 |
1992-06-16 |
Genentech, Inc. |
Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
AU687755B2
(en)
|
1992-08-21 |
1998-03-05 |
Genentech Inc. |
Method for treating an LFA-1-mediated disorder
|
|
DK0752248T3
(da)
|
1992-11-13 |
2000-11-13 |
Idec Pharma Corp |
Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
|
|
US6037454A
(en)
|
1996-11-27 |
2000-03-14 |
Genentech, Inc. |
Humanized anti-CD11a antibodies
|
|
US5888809A
(en)
|
1997-05-01 |
1999-03-30 |
Icos Corporation |
Hamster EF-1α transcriptional regulatory DNA
|
|
ZA986596B
(en)
|
1997-07-25 |
1999-02-08 |
Schering Corp |
Mammalian cytokine related reagents
|
|
US6060284A
(en)
|
1997-07-25 |
2000-05-09 |
Schering Corporation |
DNA encoding interleukin-B30
|
|
WO1999040195A1
(en)
|
1998-02-06 |
1999-08-12 |
Schering Corporation |
Mammalian receptor proteins; related reagents and methods
|
|
DE69942607D1
(de)
|
1998-04-14 |
2010-09-02 |
Chugai Pharmaceutical Co Ltd |
Neues cytokinartiges protein
|
|
US7090847B1
(en)
|
1999-09-09 |
2006-08-15 |
Schering Corporation |
Mammalian cytokines; related reagents and methods
|
|
AU780163B2
(en)
|
1999-09-09 |
2005-03-03 |
Merck Sharp & Dohme Corp. |
Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
|
|
US6756481B2
(en)
|
2000-05-10 |
2004-06-29 |
Schering Corporation |
IL-23 receptor binding compositions
|
|
US7422743B2
(en)
|
2000-05-10 |
2008-09-09 |
Schering Corporation |
Mammalian receptor protein DCRS5;methods of treatment
|
|
US20050039222A1
(en)
|
2001-10-24 |
2005-02-17 |
Kiyoshi Habu |
Sgrf gene-modified non-human animals
|
|
IL161677A0
(en)
|
2001-11-08 |
2004-09-27 |
Protein Design Labs |
Stable liquid pharmaceutical formulation of igg antibodies
|
|
WO2004042009A2
(en)
|
2002-10-30 |
2004-05-21 |
Genentech, Inc. |
Inhibition of il-17 production
|
|
WO2004058178A2
(en)
|
2002-12-23 |
2004-07-15 |
Schering Corporation |
Uses of mammalian cytokine; related reagents
|
|
US20040219150A1
(en)
|
2003-02-06 |
2004-11-04 |
Cua Daniel J. |
Uses of mammalian cytokine; related reagents
|
|
US7282204B2
(en)
|
2003-03-10 |
2007-10-16 |
Schering Corporation |
Uses of IL-23 agonists and antagonists; related reagents
|
|
US7413894B2
(en)
|
2003-07-01 |
2008-08-19 |
University Of Virginia Patent Foundation |
TAG-1 and TAG-2 proteins and uses thereof
|
|
KR101128777B1
(ko)
|
2003-11-04 |
2012-04-13 |
조마 테크놀로지 리미티드 |
다발성 골수종을 치료하기 위한 길항제 항-ｃｄ４０단클론성 항체의 용도
|
|
ATE447412T1
(de)
|
2003-11-04 |
2009-11-15 |
Novartis Vaccines & Diagnostic |
Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
|
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
|
CN1942201B
(zh)
|
2004-02-17 |
2012-06-20 |
先灵公司 |
调节il-23活性的方法；相关试剂
|
|
US20050287593A1
(en)
|
2004-05-03 |
2005-12-29 |
Schering Corporation |
Use of cytokine expression to predict skin inflammation; methods of treatment
|
|
BRPI0510617A
(pt)
|
2004-05-03 |
2007-10-30 |
Schering Corp |
uso de expressão de il-17 para prever inflamação de pele; processos de tratamento
|
|
WO2006036922A2
(en)
|
2004-09-27 |
2006-04-06 |
Centocor, Inc. |
Srage mimetibody, compositions, methods and uses
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
US7820168B2
(en)
|
2004-12-20 |
2010-10-26 |
Schering Corporation |
Treatment of diabetes using antibodies to IL-23, IL-23 receptor and IL-17
|
|
SI2452694T1
(sl)
|
2005-06-30 |
2019-05-31 |
Janssen Biotech, Inc. |
Protitelesa proti-IL-23, sestavki in postopki uporabe
|
|
CA2612785A1
(en)
|
2005-06-30 |
2007-01-11 |
Archemix Corp. |
Polynucleotides and polypeptides of the il-12 family of cytokines
|
|
DE602006015830D1
(de)
|
2005-08-25 |
2010-09-09 |
Lilly Co Eli |
Anti-il-23-antikörper
|
|
PT1931710T
(pt)
|
2005-08-31 |
2017-03-28 |
Merck Sharp & Dohme |
Anticorpos anti-il-23 manipulados
|
|
US20080199460A1
(en)
|
2005-09-01 |
2008-08-21 |
Schering Corporation |
Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
|
|
CN101389769A
(zh)
*
|
2005-12-28 |
2009-03-18 |
森托科尔公司 |
用于评价和治疗银屑病及相关疾病的标记与方法
|
|
HUE034269T2
(en)
|
2005-12-29 |
2018-02-28 |
Janssen Biotech Inc |
Human anti-IL-23 antibodies, preparations, methods and applications
|
|
US7790862B2
(en)
|
2006-06-13 |
2010-09-07 |
Zymogenetics, Inc. |
IL-17 and IL-23 antagonists and methods of using the same
|
|
US7910703B2
(en)
|
2006-03-10 |
2011-03-22 |
Zymogenetics, Inc. |
Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
|
|
US20080311043A1
(en)
|
2006-06-08 |
2008-12-18 |
Hoffman Rebecca S |
Uses and compositions for treatment of psoriatic arthritis
|
|
WO2007149814A1
(en)
|
2006-06-19 |
2007-12-27 |
Wyeth |
Methods of modulating il-22 and il-17
|
|
CA2674608A1
(en)
|
2007-01-09 |
2008-07-17 |
Wyeth |
Anti-il-13 antibody formulations and uses thereof
|
|
TWI426918B
(zh)
|
2007-02-12 |
2014-02-21 |
Merck Sharp & Dohme |
Ｉｌ-２３拮抗劑於治療感染之用途
|
|
CA2675602A1
(en)
|
2007-02-16 |
2008-08-21 |
Wyeth |
Protein formulations containing sorbitol
|
|
JP2010518858A
(ja)
|
2007-02-23 |
2010-06-03 |
シェーリング コーポレイション |
操作された抗−ｉｌ−２３ｐ１９抗体
|
|
ES2708988T3
(es)
|
2007-02-23 |
2019-04-12 |
Merck Sharp & Dohme |
Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
|
|
CA2679400A1
(en)
|
2007-02-28 |
2008-09-04 |
Schering Corporation |
Combination therapy for treatment of immune disorders
|
|
WO2009032954A1
(en)
|
2007-09-04 |
2009-03-12 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
|
|
AR068723A1
(es)
|
2007-10-05 |
2009-12-02 |
Glaxo Group Ltd |
Proteina que se une a antigenos que se une a il-23 humana y sus usos
|
|
WO2009053493A1
(en)
*
|
2007-10-26 |
2009-04-30 |
Galderma Research & Development |
Non-invasive method to perform skin inflammatory disease pharmaco-genomic studies and diagnosis method thereof
|
|
CA2607771A1
(en)
|
2007-11-01 |
2009-05-01 |
Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence |
Humanized anti-venezuelan equine encephalitis virus recombinant antibody
|
|
US8420081B2
(en)
|
2007-11-30 |
2013-04-16 |
Abbvie, Inc. |
Antibody formulations and methods of making same
|
|
WO2009082624A2
(en)
|
2007-12-10 |
2009-07-02 |
Zymogenetics, Inc. |
Antagonists of il-17a, il-17f, and il-23 and methods of using the same
|
|
KR20160116056A
(ko)
|
2008-08-14 |
2016-10-06 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
항-ｉｌ-12/ｉｌ-23 항체
|
|
EP2331078B1
(en)
|
2008-08-27 |
2012-09-19 |
Merck Sharp & Dohme Corp. |
Lyophilized formulations of engineered anti-il-23p19 antibodies
|
|
JP2012507723A
(ja)
|
2008-11-03 |
2012-03-29 |
シェーリング コーポレイション |
炎症性腸疾患生物マーカーおよび関連治療方法
|
|
US8420089B2
(en)
|
2008-11-25 |
2013-04-16 |
Alderbio Holdings Llc |
Antagonists of IL-6 to raise albumin and/or lower CRP
|
|
US20120128689A1
(en)
|
2009-04-01 |
2012-05-24 |
Glaxo Group Limited |
Anti-il-23 immunoglobulins
|
|
WO2010115092A2
(en)
|
2009-04-02 |
2010-10-07 |
The Johns Hopkins University |
Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer
|
|
EP2456787A4
(en)
|
2009-07-24 |
2013-01-30 |
Univ Leland Stanford Junior |
CYTOKIN COMPOSITIONS AND METHOD FOR THEIR USE
|
|
JO3244B1
(ar)
|
2009-10-26 |
2018-03-08 |
Amgen Inc |
بروتينات ربط مستضادات il – 23 البشرية
|
|
CN102740888B
(zh)
|
2009-11-24 |
2016-10-12 |
奥尔德生物制药公司 |
Il-6抗体及其用途
|
|
CN102695465A
(zh)
|
2009-12-02 |
2012-09-26 |
斯帕泰克医疗股份有限公司 |
结合具有可偏转柱和复合脊柱杆的骨锚固件的小轮廓脊柱假体
|
|
GB201013975D0
(en)
|
2010-08-20 |
2010-10-06 |
Imp Innovations Ltd |
Method of treating desease
|
|
JP2013520426A
(ja)
|
2010-02-18 |
2013-06-06 |
ブリストル−マイヤーズ スクイブ カンパニー |
Ｉｌ−２３に結合する、フィブロネクチンをベースとする足場ドメインタンパク質
|
|
EP3409289B1
(en)
|
2010-02-26 |
2020-09-30 |
Novo Nordisk A/S |
Stable antibody containing compositions
|
|
NZ602685A
(en)
|
2010-03-01 |
2014-10-31 |
Cytodyn Inc |
Concentrated protein formulations and uses thereof
|
|
EP2583098B1
(en)
*
|
2010-06-15 |
2018-08-08 |
Celgene Corporation |
Biomarkers for the treatment of psoriasis
|
|
US20110311527A1
(en)
|
2010-06-16 |
2011-12-22 |
Allergan, Inc. |
IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
|
|
WO2012009760A1
(en)
|
2010-07-20 |
2012-01-26 |
Cephalon Australia Pty Ltd |
Anti-il-23 heterodimer specific antibodies
|
|
EP2640745B1
(en)
|
2010-09-10 |
2018-11-07 |
MedImmune Limited |
Bivalent and bispecific anti-il6/anti-il23 antibodies
|
|
MX2019000046A
(es)
|
2010-11-04 |
2023-10-05 |
Boehringer Ingelheim Int |
Anticuerpos anti-il-23.
|
|
GB201100282D0
(en)
*
|
2011-01-07 |
2011-02-23 |
Ucb Pharma Sa |
Biological methods
|
|
TW201309330A
(zh)
|
2011-01-28 |
2013-03-01 |
Abbott Lab |
包含糖基化抗體之組合物及其用途
|
|
US9078894B2
(en)
|
2011-02-04 |
2015-07-14 |
Ab Science |
Treatment of severe persistant asthma with masitinib
|
|
PL3326649T3
(pl)
|
2012-05-03 |
2022-04-25 |
Boehringer Ingelheim International Gmbh |
Przeciwciała anty-il-23p19
|
|
ES2729603T3
(es)
|
2012-06-27 |
2019-11-05 |
Merck Sharp & Dohme |
Anticuerpos IL-23 antihumanos cristalinos
|
|
SG11201507483PA
(en)
|
2013-03-15 |
2015-10-29 |
Amgen Inc |
Methods for treating crohn's disease using an anti-il23 antibody
|
|
SG11201507482UA
(en)
|
2013-03-15 |
2015-10-29 |
Amgen Inc |
Methods for treating psoriasis using an anti-il-23 antibody
|
|
KR20140119396A
(ko)
|
2013-03-29 |
2014-10-10 |
삼성전자주식회사 |
단백질 약물의 액상 제형
|
|
EP3708679A1
(en)
*
|
2014-07-24 |
2020-09-16 |
Boehringer Ingelheim International GmbH |
Biomarkers useful in the treatment of il-23a related diseases
|
|
EA202193002A2
(ru)
|
2014-09-03 |
2022-03-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Соединение, нацеленное на ил-23a и фно-альфа, и его применение
|
|
AU2016215535B2
(en)
|
2015-02-04 |
2021-09-16 |
Boehringer Ingelheim International Gmbh |
Methods of treating inflammatory diseases
|
|
WO2017015433A2
(en)
|
2015-07-23 |
2017-01-26 |
Boehringer Ingelheim International Gmbh |
Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
|
|
TWI811716B
(zh)
|
2015-09-18 |
2023-08-11 |
德商百靈佳殷格翰國際股份有限公司 |
治療發炎性疾病之方法
|